Q2 2026 Laurus Labs Ltd Earnings Call Transcript
Key Points
- Laurus Labs Ltd (BOM:540222) reported robust revenue growth with a 35% increase in Q2, driven by strong demand in ARV and CDMO segments.
- The company achieved a significant improvement in gross margins, reaching nearly 60%, attributed to a better product mix and increased commercial molecule deliveries in CDMO.
- Laurus Labs Ltd (BOM:540222) received a 532-acre land allotment for a new pharmaceutical manufacturing complex, with plans to invest $600 million over eight years, enhancing its global manufacturing capabilities.
- The CDMO division recorded a healthy growth of 88% in H1, driven by mid to late-phase program deliveries and increased sales from new manufacturing assets.
- The company successfully passed 65 quality audits by multiple customers and regulatory agencies without any critical findings, indicating strong compliance and operational standards.
- Despite the revenue growth, Laurus Labs Ltd (BOM:540222) faces challenges with high CapEx investments, which may compress return on capital employed in the short term.
- The company has a significant net debt of INR 2,100 crore, with a debt-to-EBITDA ratio of 1.3x, which could impact financial flexibility.
- There is a potential risk of margin volatility due to ongoing large-scale investments in new modalities and manufacturing capacities.
- The working capital cycle for the CDMO business is longer due to complex synthesis processes, which could affect cash flow management.
- The company is undergoing a transition with significant CapEx in new areas like ADCs and gene therapy, which may take time to yield returns, posing a risk of delayed profitability.
Ladies and gentlemen, good day and welcome to the Laurus Labs 2Q FY26 earnings conference call hosted by DAM Capital. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Nitin Agarwal from DAM Capital. Thank you and over to you, sir.
I, thank you. Hi, good afternoon, everyone, and a very warm welcome to Laurus labs due to a 26 earnings call hosted by DAM Capital Advisors Limited.
On the call today, we have, representing Laura labs management, Doctor Satanarayan Chava, founder and CEO, Mr.
VV Ravi Kumar, executive director, Mr. Krishna Chattanahawa, ED head and head CDMO, Mrs. Sonia Chawa, ED Generics and commercial. And Mr. Vivek Kumar, EP Investor Relations, before we proceed, I would like to remind you that some of the statements made during the call today could be forward-looking in nature, and a safe harbor statement to this effect has been included in the press release that has been shared on the company's website.
I now find over the call to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
